ClinicalTrials.gg
CompletedNCT03325387Updated Aug 16, 2018

A Study of Multiple Doses of LY3305677 in Healthy Participants

A Phase 1 interventional study of LY3305677 and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-16.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The purposes of this study are to determine:

  • The safety of LY3305677 and any side effects that might be associated with it.
  • How much LY3305677 gets into the bloodstream and how long it takes the body to remove it in healthy participants, including those of Japanese origin.
  • The effect LY3305677 has on the body, particularly the effect on blood glucose levels.

This study will last approximately 17 weeks not including screening. Screening is required within 4 weeks prior to start of the study.

This study is for research purposes only and is not intended to treat any medical conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 536 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined by medical history and physical examination
  • Women not of due to surgical sterilization confirmed by medical history or menopause
  • Are first-generation Japanese or non-Japanese. First-generation Japanese is defined as the participant, the participant's biological parents, and all of the participant's grandparents are of exclusive Japanese descent and have been born in Japan
  • Have a body weight of more than 54 kilograms (kg)

Exclusion criteria

Exclusion Criteria:

  • Currently enrolled in a clinical study or have participated in a study within the past 3 months
  • Have an abnormality in the 12-lead (ECG) at screening
  • Have history of pancreatitis
  • Have known or ongoing psychiatric disorders
  • Have undergone bariatric surgery or have used any drugs for weight loss
  • Have a history of alcoholism
  • Currently smoke more than 10 cigarettes a day
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    LY3305677

    Escalating doses of LY3305677 administered by subcutaneous (SC) injection

    Drug: LY3305677

  • Placebo comparator
    Placebo

    Saline solution administered by SC injection

    Drug: Placebo

Interventions

  • Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline through 115 days

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3305677

    PK: Cmax of LY3305677

    Time frame: Days 1 and 29: Predose through 168 hours post dose

  2. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3305677

    PK: AUC of LY3305677

    Time frame: Days 1 and 29: Predose through 168 hours post dose

07

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Leeds, West Yorkshire LS2 9LH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Aug 2018, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Oct 30, 2017
StartActual
Oct 27, 2017
Primary completionActual
Aug 3, 2018
CompletionActual
Aug 3, 2018
Last update
Aug 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03325387
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
Oct 27, 2017
Primary completion
Aug 3, 2018
Completion
Aug 3, 2018
Last update
Aug 16, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion